LTGO · Latigo Biotherapeutics, Inc. · Financials
The latest filing states the doubt was alleviated.
“Accordingly, the prior substantial doubt about the Company's ability to continue as a going concern has been alleviated.”View the 10-Q filed Sep 3, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Convertible notes payable, including current maturities | 2026-06-30 | USD 35,000,000 | 10-Q filed 2026-09-03 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Current operating lease liabilities | 2026-06-30 | USD 705,000 | 10-Q filed 2026-09-03 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 648,000 | 10-Q filed 2026-09-03 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 298 similar-size Biotechnology companies (of 565 listed).